



RNS Document Posted

Lansen's Interim Results

CATHAY INTERNATIONAL HOLDINGS LD

Released 14:33:36 27 August 2020

RNS Number : 3686X
 Cathay International Holdings Ld
 27 August 2020

Cathay International Holdings Limited ("Cathay" or the "Company")

Lansen reports interim results for the six months ended 30 June 2020

Hong Kong, 27 August 2020 - Cathay International Holdings Limited (LSE: CTI.L), an operator and investor in the growing healthcare sector in the People's Republic of China, today notes that Lansen Pharmaceutical Holdings Ltd ("Lansen") (HKEX: 503), the Company's 52.83% owned subsidiary, has reported its interim results for the six months ended 30 June 2020 in accordance with the requirements of its Hong Kong listing.

The full text of the Lansen Announcement can be found at <https://www1.hkexnews.hk/listedco/listconews/sehk/2020/0827/2020082701536.pdf> and will also be made available at Announcements & Notices section of Lansen's homepage at <http://holding.lansen.com.cn/en/newslst.aspx?NodeCode=10002000700050005>.

As previously announced, Cathay will issue its Interim Results for the six months ended 30 June 2020 on Friday 28 August 2020.

-Ends-

For further enquiries, please contact:

Cathay International Holdings Limited

Eric Siu (Finance Director)

Tel: +852 2828 9289

Patrick Sung (Director and Controller)

SPARK Advisory Partners Limited (sponsor)

Andrew Emmott / James Keeshan

Tel: +44 (0) 20 3368 3555

About Cathay

Cathay International Holdings Limited (LSE: CTI.L) is a main market listed investment holding company and an operator and investor in the healthcare sector in the People's Republic of China (the "PRC"). The Company and its subsidiaries (collectively the "Group") aim to leverage on investment opportunities in the growing domestic demand for high quality healthcare products in the PRC and build portfolio companies into market sector leaders with competitive edge. Cathay has already demonstrated a track record of identifying investment opportunities in this area including: Lansen, a leading specialty pharmaceutical company focused on rheumatology and dermatology in the PRC; Haizi, a company engaged in the manufacture, marketing and sale of inositol and its by-product, di-calcium phosphate; Natural Dailyhealth, a company engaged in production and sales of plant extracts for use as key active ingredients in healthcare products; and Botai, a company engaged in collagen products.

The Group employs approximately 1,300 people across the PRC, including over 20 specialist corporate and business development staff based at the holding company's offices in Hong Kong and Shenzhen. Cathay also has a hotel investment. For more information please visit the Company's website: www.cathay-intl.com.hk.

About Lansen

Lansen, whose shares are listed on the main board of the Hong Kong Stock Exchange, is a 52.83% owned subsidiary of Cathay. Lansen is engaged in the manufacture, distribution and development of specialty prescription drugs for treatment of autoimmune disorder in rheumatology and dermatology. Lansen has established an extensive distribution network, covering more than 1,500 hospitals in four municipalities, 22 provinces and cities in the PRC. For more information please visit the Lansen's website: www.lansen.com.cn/en/index.aspx.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DOCKKOBNNBKDKFB

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. [Terms and conditions](#), including restrictions on use and distribution apply.

© 2020 London Stock Exchange plc. All rights reserved.